Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,237 people get ACHN articles and Market Currents by email alert.

Get email alerts on ACHN »

ACHN

Achillion Pharmaceuticals, Inc.

5/24/2013, 4:53 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 12:23 PM Achillion Pharmaceuticals (ACHN -1.4%) slips today in spite of reporting a Q1 result that beat Street expectations this morning. The drug developer reported a net loss of $11.7M, or $0.14 per share, compared to consensus estimates of a loss of $0.15. No revenue was recognized during the quarter. However, losses were higher than the same period last year, which came in at a loss of $9.1M, or $0.13 per share, on revenues of $2.5M. Comment! [Healthcare, Earnings, On the Move]
Tuesday, April 23, 8:55 AM Achillion Pharmaceuticals (ACHN) falls after announcing results from a Phase 2 trial for ACH-3102, a NS5A protein inhibitor. Shares off 3% premarket. 4 Comments [Healthcare, On the Move]
Friday, February 22, 2:35 PM Achillion Pharmaceuticals (ACHN +3%) trades up after pricing its offering of 15M shares at $8.40, just a slight 1.2% discount to Thursday's close. The company plans to use the roughly $120M to continue clinical testing of its hepatitis C drugs as well as general corporate expenses. Comment! [Healthcare, On the Move]
Wednesday, February 20, 7:30 PM Achillion Pharmaceuticals (ACHN): Q4 EPS of -$0.14 beats by $0.06. Revenue of $118K. Shares -7.4% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Wednesday, February 20, 6:01 PM After-hours top gainers, as of 5:30 p.m.: PEGA +18%. SID +16%. MKTG +7%. MTG +7%. CAR +6%.
After-hours top losers: RBCN -19%. TSLA -8%. ACHN -8%. HPY -6%. TXRH -6%. Comment! [On the Move]
Wednesday, February 20, 4:19 PM Achillion Pharmaceuticals (ACHN) announces a $125M secondary offering. Citigroup and Leerink Swann are acting as joint book-runners. The offering is subject to market conditions, with the actual size and terms not yet disclosed. Shares -5.6% AH. Comment! [Healthcare, On the Move]
Monday, January 7, 12:45 PM Midday top 10 gainers: PPHM +67%. MDCI +28%. DLGC +24%. EPOC +22%. BIOL +21%. RFIL +21%. BITA +16%. PRGN +15%. CHRM +15%. CBMX +15%.
Midday top 10 Losers: HILL -20%. ESI -17%. STP -13%. SWSH -11%. PGRX -11%. PSEM -11%. IHT -11%. CDXS -10%. ACHN -10%. NED -9%. Comment! [On the Move]
Monday, January 7, 8:31 AM Achillion's (ACHN +3.2%) ACH-3102 medicine for chronic hepatitis C viral infections, in combination with antiviral drug ribavirin, has performed well so far in a Phase 2a study of 8 patients. The treatment "resulted in the rapid reduction in HCV RNA accompanied by normalization of liver enzymes." The combo also appears to be safe and well tolerated. (PR) 2 Comments [Healthcare, On the Move]
Wednesday, January 2, 10:14 AM SA author Regarded Solutions bangs the table for Achillion Pharmaceuticals (ACHN +5.1%), citing its "wonderful balance sheet" and its four hepatitis C drugs, which could, "for all intents and purposes," cure the illness if approved. Achillion's promise has brought it several upgrades and made it a potential takeover target. Comment! [Healthcare, On the Move]
Monday, November 12, 2012, 1:43 PM Shares of Achillion (ACHN -11%) drop hard on the back of competitor Gilead's (GILD +12%) positive results from Phase 2 testing of its Hep C antiviral drug ribavirin. ACHN is developing its own hepatitis C virus treatment which has performed well in tests. Wells Fargo's Brian Abraham says ACHN is "well-positioned" to participate in the HCV market, and today's weakness creates a buying opportunity. Comment! [Healthcare, On the Move]
Tuesday, October 16, 2012, 12:36 PM Achillion (ACHN +4.6%) gains on a price target increase to $17 from $12 at Deutsche Bank. The firm says liver abstracts from Bristol-Myers (BMY +0.6%) and Abbott (ABT +0.1%) bode well for the future success of ACHN's two drug combo regimens for the treatment of hepatitus C virus. The firm made similar comments yesterday about Gilead (GILD +1.6%). Comment! [Healthcare, On the Move]
Friday, September 28, 2012, 12:30 PM Cowen thinks Achillion (ACHN +1.6%) is likely to be acquired by a biopharm company in need of a hep C pipeline, and considering yesterday's announcement of positive Phase 1a trial results for its drug ACH-3102, the risk/reward profile looks favorable. The company hosted an Analyst Day meeting to discuss ACH-3102 today, and Cowen thinks the company successfully made the case for differentiating it from other first generation hep C drugs. Comment! [Healthcare, On the Move]
Thursday, September 27, 2012, 9:10 AM Premarket gainers: ROYL +38.46%. TPX +14.53%. THO +8.63%. ACHN +6.53%.
Losers: PPHM -23%. Comment! [On the Move]
Thursday, September 27, 2012, 8:37 AM Achillion (ACHN +6.5%) discloses positive proof-of-concept results for ACH-3102 for treating chronic hepatitis C viral infections (HCV). The company has now initiated a phase II study for the drug. Achillion is hosting an analyst day today, with a live Webcast beginning at 1:00 pm ET. (PR) Comment! [Healthcare, On the Move]
Wednesday, September 19, 2012, 9:28 AM BofA revises its stance on a pair of hepatitis-C drugmakers, raising Achillion Pharma (ACHN) to Buy and cutting Idenix Pharma (IDIX) to Neutral. The firm is more optimistic on the market potential for ACHN’s hepatitis-C drug combo, and hikes its share price target to $13 from $7. But IDIX faces difficulties after the FDA placed a clinical hold on one of its hep-C treatments. ACHN +13.5%, IDIX -5.5% premarket. Comment! [Healthcare, Quick Ideas, On the Move]
Wednesday, September 19, 2012, 9:10 AM Premarket gainers: ACHN +12%. DCTH +9%. CPRX +9%. CBRL +7%. DRYS +7%. BVSN +6%. ANTH +6%.
Losers: IDIX -9%. GTAT -7%. 1 Comment [On the Move]